Hair Growth Treatment
Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…
Read More
Kintor Pharmaceutical has recently announced the enrollment of its first participant in its “Pivotal Clinical Trial”. This is a Phase 2/3 trial in which men with androgenic alopecia will be treated with either vehicle control, 0.5%, or 1% topical for 24 weeks. The trial will be conducted in China, with 222 patients enrolled in each…
Read More
Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men. What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…
Read More
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Read More
Equillium, a clinical-stage biotechnology company, has reported its findings from a phase 2 study of EQ101, a new treatment for patients with moderate to severe alopecia areata (AA). What is EQ101? EQ101 is a first-in-class, selective, tri-specific inhibitor that targets IL-2, IL-9, and IL-15 proteins involved in the immune response. These proteins have been implicated…
Read More
Lumenis Be. Ltd, an energy-based medical device company specializing in aesthetic and eye care solutions, has introduced FoLix™, a fractional laser system for treating hair loss. Recently cleared by the FDA, FoLix is the first fractional laser to be cleared for hair loss treatment for both women and men in the United States. What is…
Read More
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
Read More
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Read More
Follicle Thought is pleased to present a recent interview we conducted with Geoff Hamilton, the CEO of Stemson Therapeutics. Stemson Therapeutics is a biotech company founded in 2018 that aims to revolutionize hair regrowth through stem cell technology. So, let’s get into the interview. FT: Hi Geoff, Thank you for coming back to Follicle Thought…
Read More
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Read More